Timothy P. Noyes - Mar 7, 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Mar 7, 2023
Transactions value $
$0
Form type
4
Date filed
3/8/2023, 05:00 PM
Previous filing
Mar 3, 2023
Next filing
Apr 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +139K $0.00 139K Mar 7, 2023 Common Stock 139K $23.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on April 7, 2023.